Welcome to our dedicated page for Hyperliquid Strategies SEC filings (Ticker: PURR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page is intended to provide access to SEC filings for Hyperliquid Strategies Inc (NASDAQ: PURR), a company that describes itself as a digital asset treasury business focused on accumulating HYPE, the native token of the Hyperliquid blockchain. While specific filings may vary over time, SEC documents are the primary source for detailed information about the company’s operations, risks, and capital structure.
In its public descriptions, Hyperliquid Strategies Inc highlights activities such as staking, yield optimization, and active engagement in the Hyperliquid ecosystem as part of its approach to generating returns from HYPE. When available, core filings such as annual reports on Form 10-K and quarterly reports on Form 10-Q can provide additional context on how these activities are reflected in the company’s financial statements, risk factors, and management discussion.
For investors tracking PURR, SEC filings can also shed light on matters such as stock repurchase programs authorized by the Board of Directors, the company’s use of cash in connection with its HYPE-focused strategy, and other capital allocation decisions. Current reports on Form 8-K, when filed, may discuss material events, including changes to repurchase authorizations or other significant corporate actions.
Stock Titan enhances access to these documents with AI-powered summaries
Hyperliquid Strategies Inc reported that chief operating officer Jeroen Nieuwkoop received 31,840 shares of common stock in a zero‑price transaction on December 4, 2025. The filing shows this as a direct holding, giving him beneficial ownership of 31,840 shares after the transaction.
The transfer stems from the company’s recently completed business combination. On December 2, 2025, Hyperliquid Strategies completed a business combination under a Business Combination Agreement with Sonnet BioTherapeutics Holdings, Inc. and related entities. In connection with that closing, Rorschach Capital LLC received 6,580,800 shares of Hyperliquid Strategies common stock and subsequently distributed 31,840 of those shares to Mr. Nieuwkoop as a member of Rorschach Capital LLC.
Hyperliquid Strategies Inc's Chief Operating Officer, Jeroen Nieuwkoop, filed an initial insider ownership report (Form 3) for the company’s common stock. The filing states in the remarks that no securities are beneficially owned, meaning the officer reported holding no Hyperliquid Strategies Inc shares as of the event date of 12/02/2025.
Hyperliquid Strategies Inc director Mr. Diamond reported acquiring 636,800 shares of the company’s common stock in a transaction dated December 4, 2025. The shares were distributed to him by Rorschach Capital LLC, of which he is a member, after that entity received 6,580,800 common shares at the closing of Hyperliquid’s previously announced business combination with Sonnet BioTherapeutics Holdings, Inc. and related parties.
Following this distribution, Mr. Diamond beneficially owns 636,800 shares of Hyperliquid Strategies Inc common stock, held directly.
Hyperliquid Strategies Inc director reported receiving 23,880 shares of common stock through a distribution from Rorschach Capital LLC. Following this transaction, the director beneficially owns 23,880 common shares directly.
The disclosure explains that on December 2, 2025, the company completed a previously announced business combination under a Business Combination Agreement with Sonnet BioTherapeutics Holdings, Inc. and related entities. In connection with the closing, Rorschach Capital LLC received an aggregate of 6,580,800 shares of Hyperliquid Strategies common stock, and on December 4, 2025 it distributed 23,880 shares to Mr. Rosengren, a member of Rorschach Capital LLC.
Hyperliquid Strategies Inc. director reported receiving 23,880 shares of common stock on December 4, 2025, as disclosed in a Form 4 insider filing. The shares were acquired through a distribution from Rorschach Capital LLC, where the director is a member, and are shown as directly owned following the transaction.
The distribution came shortly after the completion of Hyperliquid Strategies Inc.'s previously announced business combination on December 2, 2025, under a Business Combination Agreement with Sonnet BioTherapeutics Holdings, Inc., Rorschach I LLC, TBS Merger Sub Inc. and Rorschach Merger Sub, LLC. In connection with that closing, Rorschach Capital LLC received an aggregate 6,580,800 shares of Hyperliquid Strategies common stock, a portion of which was later distributed to the director.
Hyperliquid Strategies Inc director Nailesh Bhatt reported receiving 2,082 shares of the company’s common stock on December 2, 2025. After this transaction, she beneficially owns 2,082 common shares in a direct capacity.
The filing explains that the shares were issued in connection with the closing of a previously announced business combination between Hyperliquid Strategies Inc and Sonnet BioTherapeutics Holdings, Inc. Ms. Bhatt received the shares in exchange for certain Sonnet securities she held before the transaction closed.
Hyperliquid Strategies Inc reported that a director acquired 39,800 shares of common stock on December 4, 2025. The transaction was coded “J” and reflects an acquisition, leaving the director with 39,800 shares beneficially owned in direct form.
This acquisition came from a distribution by Rorschach Capital LLC. Two days earlier, on December 2, 2025, the Company completed a previously announced business combination under a Business Combination Agreement with Sonnet BioTherapeutics Holdings, Inc. and related entities, in which Rorschach Capital LLC had received 6,580,800 shares of Hyperliquid Strategies common stock.
Hyperliquid Strategies Inc reported that its chief executive officer and director, Mr. Schamis, acquired 95,520 shares of common stock on December 4, 2025 through a distribution from Rorschach Capital LLC.
This distribution followed the completion of Hyperliquid’s previously announced business combination on December 2, 2025, under a Business Combination Agreement with Sonnet BioTherapeutics Holdings, Inc., Rorschach I LLC and other entities, in which Rorschach Capital LLC received 6,580,800 company shares. After the reported transaction, the officer beneficially owns 95,520 shares directly.
Hyperliquid Strategies Inc’s chief financial officer reported receiving 31,840 shares of common stock, which are now held as a direct ownership position. The shares were acquired on December 4, 2025 and recorded as an acquisition transaction.
The filing explains that, in connection with the closing of a previously announced business combination on December 2, 2025, Rorschach Capital LLC received 6,580,800 shares of Hyperliquid Strategies Inc common stock. Two days later, Rorschach Capital LLC distributed 31,840 shares of that stock to Mr. Beldner, reflecting his interest as a member of Rorschach Capital LLC.
A director of Hyperliquid Strategies Inc filed an initial insider ownership report indicating they are a director of the company and the filing covers a single reporting person. In the remarks, the report states that no securities are beneficially owned by this person as of the event date of December 2, 2025. This means the director reports holding no shares or other securities of Hyperliquid Strategies Inc at that time.
FAQ
What is the current stock price of Hyperliquid Strategies (PURR)?
What is the market cap of Hyperliquid Strategies (PURR)?
